Bionano Genomics Announces 2023 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Applications
10 Janeiro 2023 - 10:00AM
Bionano Genomics, Inc. (BNGO) today announced its 2023
Symposium, which is the quintessential event for the optical genome
mapping (OGM) community to present its progress to the world. It
will feature four consecutive days of OGM presentations delivered
by 25 different customers worldwide across a wide range of genetic
diseases, cancer and cell bioprocessing applications. The Symposium
will take place virtually from January 23 to 26, 2023. During
these four days, customers will showcase their latest research
findings using OGM in constitutional, hematologic malignancies, and
solid tumor applications. Each day will feature oral customer
presentations, a live panel with Q&A and a wide range of
scientific posters within the virtual exhibition hall.
“At Bionano, we are working to transform the way the world sees
the genome,” said Erik Holmlin, PhD, president and chief
executive officer of Bionano. “Symposium is our platform for the
community of OGM users to describe its utility and how it can be
integrated with other genome analysis tools to reveal more answers
for genetic disease and cancer research applications. What
impresses me most about the lineup for 2023 is the sheer breadth of
topics, ranging from neural tube defects in prenatal testing to
homologous recombination deficiency (HRD) analysis in breast cancer
and drug development with cell bioprocessing QC.”
“We were thrilled with the engagement of the OGM community at
2022 Symposium which represented 82 different countries. We believe
our customers around the world have made tremendous progress with
the implementation of OGM in their laboratories since last year.
The lineup of researchers for our 2023 Symposium is our most
exciting to date, with over 25 global experts detailing their use
of OGM to drive discoveries across a number of clinical research
applications,” said Alka Chaubey, chief medical officer at
Bionano.
Each session of Symposium will start at 7:00 am
PST and will last approximately 3 hours. After the scientific
presentations, the speakers will join for a live panel discussion
and Q&A moderated by Dr. Chaubey. In addition, each day
will feature a scientific poster exhibit. Below is an overview of
the presentation topics for each day of the event.
Monday, January 23: Oncology- Heme
malignanciesGlobal researchers studying genomic variants
involved in hematologic malignancies will share results from
studies using OGM for research in Myelodysplastic syndromes
(MDS), Chronic lymphocytic leukemias (CLL), lymphoma and Acute
Myeloid Leukemia (AML). Speakers will highlight the use of new
tools to find more pathogenic chromosomal aberrations while also
simplifying laboratory workflows.
Tuesday, January 24: Oncology- Heme malignancies and
solid tumorsScientists and clinicians from leading
hospitals and medical research institutions in the United
States and Europe will discuss their use of OGM to
assess genomic aberrations in a wide range of hematological
malignancies and solid tumors. Experts will present the use of OGM
as a complementary technique that may be used with next-generation
sequencing (NGS) to unlock a broader spectrum of genetic variants,
generate a more complete cancer genome profile, and discover new
actionable biomarkers.
Wednesday, January 25: Constitutional Genetic
DiseasesResearchers will present their experiences using
OGM to uncover genetic variation that contributes to rare
undiagnosed genetic disease, developmental disorders and
reproductive disorders. Presentations will demonstrate how the
analysis of structural variation may increase the likelihood of
identifying actional pathogenic variants that can solve unresolved
cases, even after chromosomal microarrays and exome sequencing.
Data from large multi-site studies focusing on prenatal and
postnatal applications will be presented.
Thursday, January 26: Cell
BioprocessingPresentations will center on OGM’s ability to
outperform traditional cytogenetic methods in order to screen
producer cell lines and research cell lines for genomic instability
and off-target events, ensuring the genomic integrity and stability
of cell lines.
Symposium registration is open to all and there is no charge for
attending this event. Register today at Bionano Symposium 2023
(labroots.com).
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions
that can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen,
Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. The Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view.
For more information,
visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “may,” “will” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the anticipated benefits of the Symposium and the potential for OGM
to be adopted for applications discussed at the Symposium. Each of
these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the risks and
uncertainties associated with: the impact of adverse geopolitical
and macroeconomic events, such as the COVID-19 pandemic and the
ongoing conflict between Ukraine and Russia, on our business and
the global economy; general market conditions; changes in the
competitive landscape and the introduction of competitive
technologies or improvements to existing technologies; failure of
future study results to support those reported and discussed at the
Symposium; future study results that contradict the results
discussed and reported at the Symposium; failure of OGM to be
adopted as a cytogenetic tool for analysis of oncology, including
heme malignancies and solid tumors, constitutional genetic diseases
or samples associated with cell bioprocessing; changes in our
strategic and commercial plans; our ability to obtain sufficient
financing to fund our strategic plans and commercialization
efforts; the ability of medical and research institutions to obtain
funding to support adoption or continued use of our technologies;
and the risks and uncertainties associated with our business and
financial condition in general, including the risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2021 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik Holmlin,
CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024